Silence Therapeutics (SLN) Operating Leases (2023 - 2026)
Silence Therapeutics (SLN) posted Operating Leases of $43000.0 for Q1 2026, down 39.44% sequentially from $71000.0 in Q4 2025.
Powered by 
Analysis
Silence Therapeutics (SLN) Operating Leases (2023 - 2026) Analysis & Trends
Silence Therapeutics has reported Operating Leases for 3 years, with the latest figure at $43000.0 in Q1 2026.
- Quarterly Operating Leases changed N/A year-over-year to $43000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $43000.0 (changed N/A YoY) and the FY2025 annual result came in at $71000.0, changed N/A from the prior year.
- Operating Leases fell to $43000.0 in Q1 2026 per SLN's latest filing, from $71000.0 in the prior quarter.
- Over five years, Operating Leases peaked at $115427.1 in Q4 2023 and troughed at $43000.0 in Q1 2026.
- A 3-year average of $81606.8 and a median of $84000.0 in 2025 frame the typical range for Operating Leases.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.51 Bn | 130.66 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.24 Bn | 77.25 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.46 Bn | 58.28 Bn | 1.37 Bn |
| 4 | Moderna | 57.89 Bn | 52.75 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.02 Bn | 44.02 Bn | - |
| 6 | BeOne Medicines | 39.95 Bn | 34.85 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.49 Bn | 32.19 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.43 Bn | 27.59 Bn | - |
| 9 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 10 | Silence Therapeutics | 687.53 Mn | 615.43 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 9,000.00 |
| Mar 31, 2026 | 43,000.00 |
| Dec 31, 2025 | 71,000.00 |
| Sep 30, 2025 | 97,000.00 |
| Dec 31, 2023 | 115,427.13 |